Andrew Acheson, co-manager of the €1.4bn Pioneer SICAV - US Fundamental Growth fund, said he defended himself against August's biotech sell-off by holding established stocks with room for growth rather than "paying for the hope of the future".
The manager said the fund outperformed its Russell 1000 Growth benchmark over the last three months, despite being overweight the wider healthcare sector during a period when the NASDAQ Biotechnology index...
Reducing volatility and maximising returns
Record organic asset growth
Global economic cycle is among the longest in history
Fixed income manager takes a more cautious approach
Duff & Phelps IM selected for real estate vehicle